Matinas BioPharma(MTNB) - 2024 Q2 - Quarterly Results

Exhibit 99.1 BIOPHARMA Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 Compassionate/Expanded Use Access Program with 6 additional patients under evaluation Additional LNC platform work in inflammation and oncology completed; Company evaluating next step ...